Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT03989349

Public ClinicalTrials.gov record NCT03989349. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Study identification

NCT ID
NCT03989349
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Galderma R&D
Industry
Enrollment
787 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2019
Primary completion
Feb 22, 2022
Completion
Sep 25, 2022
Last update posted
Aug 13, 2024

2019 – 2022

United States locations

U.S. sites
47
U.S. states
21
U.S. cities
41
Facility City State ZIP Site status
Galderma Investigational Site 8749 Birmingham Alabama 35244
Galderma Investigational Site 8893 Birmingham Alabama 35244
Galderma Investigational Site 8866 Guntersville Alabama 35976
Galderma Investigational Site 8808 Scottsdale Arizona 85255
Galderma Investigational Site 8906 Bell Gardens California 90201
Galderma Investigational Site 8905 Canoga Park California 91304
Galderma Investigational Site 8577 Encinitas California 92024
Galderma Investigational Site 8673 Garden Grove California 92840
Galderma Investigational Site 8683 Los Angeles California 90033
Galderma Investigational Site 8907 Newport Beach California 92660
Galderma Investigational Site 8799 Ontario California 91762
Galderma Investigational Site 8745 Pasadena California 91105
Galderma Investigational Site 8658 San Diego California 92123
Galderma Investigational Site 8536 Santa Ana California 92705
Galderma Investigational Site 8820 Westminster California 92683
Galderma Investigational Site 8637 Farmington Connecticut 06030
Galderma Investigational Site 8875 Delray Beach Florida 33484
Galderma Investigational Site 8391 Hialeah Florida 33013
Galderma Investigational Site 8727 Hialeah Florida 33016
Galderma Investigational Site 8523 Largo Florida 33770
Galderma Investigational Site 8719 Miami Florida 33125
Galderma Investigational Site 8656 Miami Florida 33137
Galderma Investigational Site 8704 Miami Florida 33155
Galderma Investigational Site 8706 Miami Florida 33175
Galderma Investigational Site 8203 Tampa Florida 33607
Galderma Investigational Site 8839 Tampa Florida 33615
Galderma Investigational Site 8729 Rolling Meadows Illinois 60008
Galderma Investigational Site 8724 New Albany Indiana 47150
Galderma Investigational Site 8554 Detroit Michigan 48202
Galderma Investigational Site 8825 Las Vegas Nevada 89106
Galderma Investigational Site 8506 Hackensack New Jersey 07601
Galderma Investigational Site 8741 Buffalo New York 14221
Galderma Investigational Site 8723 Cortland New York 13045
Galderma Investigational Site 8733 New York New York 10022
Galderma Investigational Site 8823 Greensboro North Carolina 27408
Galderma Investigational Site 8030 Raleigh North Carolina 27612
Galderma Investigational Site 8747 Cincinnati Ohio 45219
Galderma Investigational Site 8212 Portland Oregon 97210
Galderma Investigational Site 8721 Pittsburgh Pennsylvania 15213
Galderma Investigational Site 8713 North Charleston South Carolina 29420
Galderma Investigational Site 8705 Chattanooga Tennessee 37421
Galderma Investigational Site 8807 Houston Texas 77029
Galderma Investigational Site 8618 Waco Texas 76710
Galderma Investigational Site 8003 Webster Texas 77598
Galderma Investigational Site 8672 Salt Lake City Utah 84117
Galderma Investigational Site 8896 Richmond Virginia 23219
Galderma Investigational Site 8434 Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03989349, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 13, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03989349 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →